Syngene cuts guidance as key product loss weighs on growth
Continued inventory correction for Syngene’s largest commercial biologics product drags earnings for a second straight quarter.
Continued inventory correction for Syngene’s largest commercial biologics product drags earnings for a second straight quarter.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
